Objectives:The current study is concerned with creatingSn(IV) complex with a novel synthesize schiff base ligand2,3-dimethyl-N'-(2-oxo-2,3-dihydro-1Hindol-3-yl)benzhydrazide and were investigated for the Inhibition of alphaamylase and alpha-glucosidase enzyme. Methods: Ligand was synthesized by using isatin and 2,3-dimethylbenzoic acid hydrazide. n-Bu 3 SnCl and n-Bu 2 SnCl 2 were used for the synthesis of metal complexes. The structures of the ligand and metal complexes were confirmed by spectroscopic analysis i.e. 1H-NMR, IR and MS. Findings: A clinical disease known as diabetes mellitus is defined by hyperglycemia, in which a greater than normal amount of glucose circulates in the blood plasma. Inhibitors of alpha amylase and alpha glucosidaseare used to better manage hyperglycemia in type 2 diabetes mellitus. Synthesized metal complexes were investigated for the Inhibition of alpha-amylase and alpha-glucosidase enzyme. In the alpha amylase inhibition assay, L-1 (118.88±11.14), MC-1 (76.90±9.55), and MC-2 (73.28±8.31) all displayed 50% alpha amylase inhibition activity. The IC 50 values for [L-1], [MC-1], and in the alpha glucosidase inhibition experiment were 128.86±10.27, 76.90±9.55, and 73.28±8.31 g/ml, respectively. Observed data revealed that MC-2 have higher inhibition activity. Novelty: Anti-hyperglycemia activity was investigated by using newly synthesized metal complexes.